The prognostic value of XPC is further supported by having two XPC polymorphisms, XPC 499CC and XPC 939AC+CC (939 Lys and Gln), as part of a 5-polymorphism panel (high risk genotype) that has a 79% sensitivity and 85.4% specificity of predicting 5 years progression free survival (104), indicating a potential prognostic role of XPC polymorphisms in esophageal cancer risk. The gene discussed is XPC; the disease is esophageal cancer.